scholarly journals Dexamethasone intravitreal implant in the silicone oil-filled eye for the treatment for recurrent macular oedema associated with ankylosing spondylitis: a case report

2013 ◽  
Vol 91 (4) ◽  
pp. e331-e332 ◽  
Author(s):  
Jee T. Kim ◽  
Young H. Yoon ◽  
Dong H. Lee ◽  
Soo G. Joe ◽  
June-G. Kim
Keyword(s):  
Case Report ◽  
Ankylosing Spondylitis ◽  
Macular Oedema ◽  
Silicone Oil ◽  
Dexamethasone Intravitreal Implant ◽  
Intravitreal Implant

scholarly journals Management of anterior chamber dislocation of a dexamethasone intravitreal implant: a case report

2016 ◽  
Vol 10 (1) ◽  
Author(s):  
Fernanda Pacella ◽  
Enzo Agostinelli ◽  
Sandra Cinzia Carlesimo ◽  
Marcella Nebbioso ◽  
Roberto Secondi ◽  
...  
Keyword(s):  
Case Report ◽  
Anterior Chamber ◽  
Dexamethasone Intravitreal Implant ◽  
Intravitreal Implant

scholarly journals Dexamethasone intravitreal implant in treatment-naïve diabetic macular oedema: findings from the prospective, multicentre, AUSSIEDEX study

2021 ◽  
pp. bjophthalmol-2021-319070
Author(s):  
Samantha Fraser-Bell ◽  
Hyong Kwon Kang ◽  
Paul Mitchell ◽  
Jennifer J Arnold ◽  
Jodi Tainton ◽  
...  
Keyword(s):  
Real World ◽  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Common Adverse Event ◽  
Open Label ◽  
Dexamethasone Intravitreal Implant ◽  
Intravitreal Implant ◽  
Registration Number ◽  
Treatment Naïve ◽  
Change In Mean

AimTo evaluate the effectiveness of dexamethasone intravitreal implant 0.7 mg (DEX; Ozurdex) monotherapy in the patient subgroup of the AUSSIEDEX study with treatment-naïve diabetic macular oedema (DME).MethodsThe open-label, prospective, phase 4, real-world study included pseudophakic eyes and phakic eyes scheduled for cataract surgery that were treatment-naïve or non-responsive to antivascular endothelial growth factors. No eyes were excluded based on baseline best-corrected visual acuity (BCVA) or central subfield retinal thickness (CRT). After the initial DEX injection at the baseline visit, reinjection was permitted at ≥16-week intervals. Week-16 and week-52 visits were mandatory. Primary endpoints were changes in mean BCVA and CRT from baseline to 52 weeks.ResultsOf 200 eyes enrolled in the AUSSIEDEX study, 57 were treatment-naïve. Baseline mean BCVA was 58.8 letters and baseline mean CRT was 418.6 µm; changes in mean BCVA and CRT from baseline to 52 weeks in this subgroup were 3.4 letters (p=0.042) and –89.6 µm (p<0.001), respectively, with a mean 2.5 injections. The change in mean CRT from baseline was –55.8 µm at week 16 (p<0.001). The most common adverse event was increased intraocular pressure (IOP), with 20.0% of eyes requiring IOP-lowering medication. One patient was discontinued due to increased IOP. No eyes required filtration surgery. No serious, treatment-related ocular adverse events were reported.ConclusionIn this largest prospective, real-world study of DEX monotherapy for DME to date, DEX significantly improved CRT and BCVA at 52 weeks in treatment-naïve eyes, without new safety concerns, supporting DEX use in treatment-naïve DME.Trial registration numberNCT02731911.

Sign in / Sign up

Export Citation Format

Share Document